Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 1 | -$0.43 | -$0.32 | -$0.37 |
Q2 2025 | 1 | -$0.44 | -$0.32 | -$0.38 |
Q3 2025 | 1 | -$0.43 | -$0.31 | -$0.37 |
Q4 2025 | 1 | -$0.29 | -$0.21 | -$0.25 |
Foghorn Therapeutics Inc. last posted its earnings results on Monday, November 4th, 2024. The company reported $-0.31 earnings per share for the quarter, topping analysts' consensus estimates of $-0.42 by $0.11. The company had revenue of 7.81 M for the quarter and had revenue of 34.16 M for the year. Foghorn Therapeutics Inc. has generated $-2 earnings per share over the last year ($-2.34 diluted earnings per share) and currently has a price-to-earnings ratio of -2.91. Foghorn Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 5th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/04/2024 | Q3 2024 | -$0.42 | -$0.31 | 0.11 | $6.34 M | $7.81 M |
08/08/2024 | Q2 2024 | -$0.60 | -$0.45 | 0.15 | $6.04 M | $6.89 M |
05/06/2024 | Q1 2024 | -$0.55 | -$0.59 | -0.04 | $5.05 M | |
03/07/2024 | Q4 2023 | -$0.79 | -$0.57 | 0.22 | $5.77 M | |
11/02/2023 | Q3 2023 | -$0.72 | -$0.34 | 0.38 | $4.58 M | $17.48 M |
08/04/2023 | Q2 2023 | -$0.73 | -$0.70 | 0.03 | $6.32 M | $5.60 M |
05/08/2023 | Q1 2023 | -$0.68 | -$0.73 | -0.05 | $5.31 M | |
03/09/2023 | Q4 2022 | -$0.59 | -$0.82 | -0.23 | $4.18 M | |
11/08/2022 | Q3 2022 | -$0.60 | -$0.56 | 0.04 | $9.19 M | $6.63 M |
08/09/2022 | Q2 2022 | -$0.53 | -$0.66 | -0.13 | $9.58 M | $4.49 M |
05/09/2022 | Q1 2022 | -$0.40 | -$0.63 | -0.23 | $3.92 M | |
03/10/2022 | Q4 2021 | -$0.74 | $4.62 | 5.36 | $713,000 | |
11/09/2021 | Q3 2021 | -$0.66 | -$0.71 | -0.05 | $30,750 | $41,000 |
08/10/2021 | Q2 2021 | -$0.63 | -$0.63 | 0 | $279,000 | $279,000 |
05/11/2021 | Q1 2021 | -$0.63 | -$0.62 | 0.01 | $286,000 | |
03/18/2021 | Q4 2020 | -$0.00 | $251,000 | |||
12/04/2020 | Q3 2020 | -$1.72 | -$0.51 | 1.21 | $626,333 | $179,000 |
06/29/2020 | Q2 2020 | -$0.71 | $0 | |||
03/30/2020 | Q1 2020 | -$0.63 | $0 | |||
12/30/2019 | Q4 2019 | -$0.69 | $0 |
Foghorn Therapeutics Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 5th, 2025 based off last year's report dates.
In the previous quarter, Foghorn Therapeutics Inc. (:FHTX) reported $-0.31 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.42 by $0.11.
The conference call for Foghorn Therapeutics Inc.'s latest earnings report can be listened to online.
The conference call transcript for Foghorn Therapeutics Inc.'s latest earnings report can be read online.
Foghorn Therapeutics Inc. (:FHTX) has a recorded annual revenue of $34.16 M.
Foghorn Therapeutics Inc. (:FHTX) has a recorded net income of $34.16 M. Foghorn Therapeutics Inc. has generated $-2.34 earnings per share over the last four quarters.
Foghorn Therapeutics Inc. (:FHTX) has a price-to-earnings ratio of -2.91 and price/earnings-to-growth ratio is -1.89.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED